![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score...
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of...
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.69 | -3.81426202322 | 18.09 | 19.36 | 16.485 | 41668 | 18.24018787 | CS |
4 | -0.92 | -5.02183406114 | 18.32 | 20.51 | 16.05 | 48727 | 17.84797384 | CS |
12 | -6.37 | -26.7984854859 | 23.77 | 24.11 | 15.37 | 61131 | 18.84410016 | CS |
26 | -12.49 | -41.7865506858 | 29.89 | 33 | 15.37 | 77232 | 23.01917951 | CS |
52 | -1.07 | -5.79317812669 | 18.47 | 33 | 15 | 87485 | 23.25786985 | CS |
156 | 2.93 | 20.2487906012 | 14.47 | 33 | 1.77 | 194660 | 12.73234667 | CS |
260 | -7.6 | -30.4 | 25 | 42.86 | 1.77 | 178097 | 13.60601204 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions